The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) is a huge mover today! About 143,149 shares traded hands. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has declined 8.68% since March 7, 2016 and is downtrending. It has underperformed by 16.27% the S&P500.
The move comes after 8 months positive chart setup for the $618.32 million company. It was reported on Oct, 10 by Barchart.com. We have $19.19 PT which if reached, will make NASDAQ:SCMP worth $265.88M more.
Analysts await Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to report earnings on November, 2. They expect $0.26 EPS, up 62.50% or $0.10 from last year’s $0.16 per share. SCMP’s profit will be $11.98 million for 12.90 P/E if the $0.26 EPS becomes a reality. After $0.23 actual EPS reported by Sucampo Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 13.04% EPS growth.
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Ratings Coverage
Out of 8 analysts covering Sucampo Pharma (NASDAQ:SCMP), 4 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 50% are positive. Sucampo Pharma has been the topic of 19 analyst reports since August 6, 2015 according to StockzIntelligence Inc. Roth Capital reinitiated Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) on Thursday, October 29 with “Buy” rating. Mizuho downgraded Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) on Thursday, August 4 to “Neutral” rating. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has “Buy” rating given on Wednesday, August 26 by Maxim Group. Jefferies maintained Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) rating on Thursday, August 4. Jefferies has “Hold” rating and $14 price target. The firm has “Neutral” rating given on Friday, January 15 by Mizuho. Northland Capital initiated Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) on Wednesday, September 7 with “Outperform” rating. The firm has “Hold” rating given on Friday, November 20 by Jefferies. The stock of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has “Neutral” rating given on Friday, October 9 by Mizuho. The rating was maintained by WallachBeth Capital on Thursday, August 27 with “Hold”. UBS initiated it with “Buy” rating and $20 target price in Tuesday, February 9 report.
According to Zacks Investment Research, “Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders.”
Insitutional Activity: The institutional sentiment increased to 0.98 in 2016 Q2. Its up 0.10, from 0.88 in 2016Q1. The ratio increased, as 17 funds sold all Sucampo Pharmaceuticals, Inc. shares owned while 46 reduced positions. 22 funds bought stakes while 40 increased positions. They now own 17.83 million shares or 12.41% less from 20.36 million shares in 2016Q1.
Clark Estates Ny has 225,000 shares for 0.49% of their US portfolio. Gsa Prtnrs Llp reported 82,540 shares or 0.05% of all its holdings. Princeton Alpha L P holds 0.02% or 12,616 shares in its portfolio. Tiaa Cref Investment Mgmt Ltd Liability Corporation has invested 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). California State Teachers Retirement System reported 49,118 shares or 0% of all its holdings. Meeder Asset Mngmt Incorporated holds 0.01% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 8,077 shares. Springbok Mgmt Ltd Co has 0.02% invested in the company for 11,961 shares. Tradewinds Global Investors Limited accumulated 0.02% or 23,362 shares. Ubs Asset Mgmt Americas has 13,159 shares for 0% of their US portfolio. Voya Management Lc has 0% invested in the company for 10,934 shares. Invesco holds 118,153 shares or 0% of its portfolio. Aqr Mngmt Limited Liability has 0% invested in the company for 107,079 shares. Dimensional Fund Advisors Lp has 0.01% invested in the company for 1.42M shares. Teacher Retirement Sys Of Texas holds 3,173 shares or 0% of its portfolio. Macquarie Limited accumulated 20,800 shares or 0% of the stock.
More recent Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) news were published by: Moodys.com which released: “Moody’s assigns B3 CFR to Sucampo Pharmaceuticals” on October 01, 2015. Also Bizjournals.com published the news titled: “Sucampo acquires exclusive option for cancer drug in deal worth up to $190 million” on January 11, 2016. Bizjournals.com‘s news article titled: “Bethesda pharmaceutical makes $278 million all-cash offer for Japanese company” with publication date: August 26, 2015 was also an interesting one.
SCMP Company Profile
Sucampo Pharmaceuticals, Inc., incorporated on December 9, 2008, is a biopharmaceutical company. The Firm focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology inflammatory disorders. The Firm operates through development and commercialization of pharmaceutical products segment. The Company’s activities are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts activities in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, United Kingdom.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.